IMMURX LLC

Basic Information

16 Cavendish Court
LEBANON, NH, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 781013615
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Safe and effective anti CD154 antibodies for therapeutic intervention

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): In both animal proof of concept studies and preliminary clinical trials, there is ample data demonstrating the potential therapeutic benefits o CD154 blockade for ...

    SBIR Phase I 2012 Department of Health and Human Services
  2. VISTA: A Novel Therapeutic Target That Negatively Regulates Immunity

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): We have discovered, characterized and functionally defined a novel, immune inhibitory ligand. This ligand is hematopoietically-expressed, a distant member of the B ...

    SBIR Phase I 2011 Department of Health and Human Services
  3. Preclinical Development of a Novel and Powerful Immunotherapeutic

    Amount: $2,776,441.00

    DESCRIPTION (provided by applicant): ImmuRx is developing a novel and potent immunotherapeutic product to stimulate the immune system. This will significantly increase the efficacy of existing and ne ...

    SBIR Phase II 2011 Department of Health and Human Services
  4. Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine

    Amount: $537,514.00

    DESCRIPTION (provided by applicant): The early infiltration by leukocytes into the tumor microenvironment leads to neovascularization, enhanced tumor growth, metastasis and lethality of the host. Not ...

    SBIR Phase I 2010 Department of Health and Human Services
  5. Potent Vaccine Adjuvant Therapeutic

    Amount: $577,222.00

    DESCRIPTION (provided by applicant): Protective immunity against chronic infectious diseases such as TB will almost certainly require the generation of potent cellular immunity. To that end, we have r ...

    SBIR Phase I 2009 Department of Health and Human Services
  6. Creation of an Anti-CD40 Superagonistic Monoclonal Antibody

    Amount: $329,936.00

    Description: The overall goal of this revised SBIR application is to produce and test monoclonal antibodies (mab) to human CD40 that possess super-agonistic activity, as part of an adjuvant platfor ...

    SBIR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government